Trials / Completed
CompletedNCT02262143
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia
Efficacy and Safety of Combination Therapy of Rosuvastatin and Fenofibrate Versus Rosuvastatin Monotherapy in Mixed Dyslipidemia Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 362 (actual)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of combination therapy of rosuvastatin and fenofibrate versus rosuvastatin monotherapy in mixed dyslipidemia patients: A randomized, multi-center, double-blind, phase 3 study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | Rosuvastatin 10 mg, qd, po |
| DRUG | Fenofibrate | Fenofibrate 160mg, qd, po |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2016-10-01
- Completion
- 2017-06-01
- First posted
- 2014-10-10
- Last updated
- 2018-08-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02262143. Inclusion in this directory is not an endorsement.